Celgene (CELG) Lower on Disappointing REVLIMID Data
Tweet Send to a Friend
Shares of Celgene (Nasdaq: CELG) are under heavy pressure today following the presentation of data from two Phase III front-line ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


